Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-30
2007-10-30
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S952000
Reexamination Certificate
active
10507139
ABSTRACT:
Compounds of formula Iin free or salt form, wherein Ar, X, Y, R1, R2, R3, R5, m, n, p and q have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
REFERENCES:
patent: 5095014 (1992-03-01), Taylor et al.
patent: 0 903 349 (1999-03-01), None
patent: 2 093 456 (1982-09-01), None
patent: 99/04794 (1999-02-01), None
patent: 03/007939 (2003-01-01), None
Le Grand Darren Mark
McCarthy Clive
Walker Clive Victor
Woods John James
Alexander John B.
Chung Susannah
McKane Joseph K.
Novartis AG
LandOfFree
Azetidine derivatives as CCR-3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azetidine derivatives as CCR-3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azetidine derivatives as CCR-3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3854507